News
Phase III ACTIV-3 study of MP 0420 has failed to meet endpoint in COVID-19.
Molecular Partners announced that a planned futility analysis of MP 0420 (ensovibep) in the ongoing ACTIV-3 clinical study (NCT04501978) has not met the thresholds required to continue enrollment of adults with COVID-19 in the hospitalized setting.
This global Phase III ACTIV-3 platform study is being conducted by the National Institutes of Health (NIH) as part of its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program.
ACTIV is evaluating multiple therapies for COVID-19 to see what, if any, benefit can be seen over current standard of care. At the time of the analysis, 470 patients had been randomized in the ensovibep arm of the study. Ensovibep was observed to be generally safe and well tolerated with reported side effects consistent with standard of care.
Condition: Coronavirus/COVID-19 Infection
Type: drug